Chun-Cheng Wang1,2,3, Yao-Chang Wang4, Guei-Jane Wang1,5,6, Ming-Yi Shen1, Yen-Lin Chang7, Show-Yih Liou8, Hung-Chih Chen9, An-Sheng Lee10, Kuan-Cheng Chang1,3,11,12, Wei-Yu Chen13, Chiz-Tzung Chang14,15,16. 1. Graduate Institute of Clinical Medical Science, China Medical University, No. 91, Hsueh-Shih Road, Taichung, 40402, Taiwan. 2. Division of Cardiology, Department of Internal Medicine, Taichung Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation, Taichung, Taiwan. 3. Division of Cardiovascular Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan. 4. Division of Cardiothoracic Surgery, Chang Gung Memorial Hospital Keelung Branch, Keelung, Taiwan. 5. Department of Medical Research, China Medical University Hospital, Taichung, Taiwan. 6. Department of Health and Nutrition Biotechnology, Asia University, Taichung, Taiwan. 7. Department of Biomedical Engineering, Chun Yuan Christian University, Taoyuan, Taiwan. 8. Formosan Blood Purification Foundation, Taipei, Taiwan. 9. Division of Nephrology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan. 10. Department of Medicine, Mackay Medical College, New Taipei, Taiwan. 11. College of Medicine, China Medical University, No. 91, Hsueh-Shih Road, Taichung, 40402, Taiwan. 12. Cardiovascular Research Laboratory, China Medical University Hospital, Taichung, Taiwan. 13. Graduate Institute of Basic Medical Science, China Medical University, No. 91, Hsueh-Shih Road, Taichung, 40402, Taiwan. 14. Division of Nephrology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan. d19863@mail.cmuh.org.tw. 15. College of Medicine, China Medical University, No. 91, Hsueh-Shih Road, Taichung, 40402, Taiwan. d19863@mail.cmuh.org.tw. 16. Cardiovascular Research Laboratory, China Medical University Hospital, Taichung, Taiwan. d19863@mail.cmuh.org.tw.
Abstract
BACKGROUND: Enhanced advanced glycation end products deposition within myocardial tissue may cause diastolic dysfunction. However, whether this is related to left ventricular hypertrophy or inappropriate left ventricular mass remains unclear. METHODS: We prospectively enrolled 139 subjects at risk for cardiovascular diseases. We used echocardiography for measurements of left ventricular mass and cardiac systolic and diastolic functional parameters. An advanced glycation end product reader was applied for measurements of skin autofluorescence values. Comparisons of left ventricular mass and echocardiographic parameters between the higher and lower skin autofluorescence groups were analyzed. RESULTS: Compared with the lower skin autofluorescence group, left ventricular mass index and the ratio of observed left ventricular mass/predicted left ventricular mass (oLVM/pLVM) was significantly higher in the higher skin autofluorescence group (61.22 ± 17.76 vs. 47.72 ± 11.62, P < 0.01, 1.62 ± 0.38 vs. 1.21 ± 0.21, P < 0.01). After adjustment for potential confounding factors, skin autofluorescence was an independent factor for left ventricular mass index (β = 0.32, P < 0.01) and the ratio of oLVM/pLVM (β = 0.41, P < 0.01). Skin autofluorescence ≥2.35 arbitrary unit predicted left ventricular hypertrophy at a sensitivity of 58.8%, and a specificity of 73.0% (P < 0.01). Skin autofluorescence ≥2.25 arbitrary unit predicted inappropriate left ventricular mass at a sensitivity of 71.1%, and a specificity of 83.9% (P < 0.01). Skin autofluorescence was positively correlated with E/E', an indicator for diastolic dysfunction (r = 0.21, P = 0.01). CONCLUSIONS: Skin autofluorescence is a useful tool for detecting left ventricular hypertrophy, inappropriate left ventricular mass and diastolic dysfunction.
BACKGROUND: Enhanced advanced glycation end products deposition within myocardial tissue may cause diastolic dysfunction. However, whether this is related to left ventricular hypertrophy or inappropriate left ventricular mass remains unclear. METHODS: We prospectively enrolled 139 subjects at risk for cardiovascular diseases. We used echocardiography for measurements of left ventricular mass and cardiac systolic and diastolic functional parameters. An advanced glycation end product reader was applied for measurements of skin autofluorescence values. Comparisons of left ventricular mass and echocardiographic parameters between the higher and lower skin autofluorescence groups were analyzed. RESULTS: Compared with the lower skin autofluorescence group, left ventricular mass index and the ratio of observed left ventricular mass/predicted left ventricular mass (oLVM/pLVM) was significantly higher in the higher skin autofluorescence group (61.22 ± 17.76 vs. 47.72 ± 11.62, P < 0.01, 1.62 ± 0.38 vs. 1.21 ± 0.21, P < 0.01). After adjustment for potential confounding factors, skin autofluorescence was an independent factor for left ventricular mass index (β = 0.32, P < 0.01) and the ratio of oLVM/pLVM (β = 0.41, P < 0.01). Skin autofluorescence ≥2.35 arbitrary unit predicted left ventricular hypertrophy at a sensitivity of 58.8%, and a specificity of 73.0% (P < 0.01). Skin autofluorescence ≥2.25 arbitrary unit predicted inappropriate left ventricular mass at a sensitivity of 71.1%, and a specificity of 83.9% (P < 0.01). Skin autofluorescence was positively correlated with E/E', an indicator for diastolic dysfunction (r = 0.21, P = 0.01). CONCLUSIONS: Skin autofluorescence is a useful tool for detecting left ventricular hypertrophy, inappropriate left ventricular mass and diastolic dysfunction.
Entities:
Keywords:
Advanced glycation end product; Diastolic dysfunction; Inappropriate left ventricular mass; Skin autofluorescence
Authors: Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista Journal: J Am Soc Echocardiogr Date: 2009-02 Impact factor: 5.251
Authors: Jasper W L Hartog; Suzan Willemsen; Dirk J van Veldhuisen; Jan L Posma; Leen M van Wijk; Yoran M Hummel; Hans L Hillege; Adriaan A Voors Journal: Eur J Heart Fail Date: 2011-06-13 Impact factor: 15.534
Authors: Giovanni Cioffi; Luigi Tarantini; Roberto Frizzi; Carlo Stefenelli; Tiziano E Russo; Alessandro Selmi; Chiara Toller; Francesco Furlanello; Giovanni de Simone Journal: J Hypertens Date: 2011-03 Impact factor: 4.844
Authors: Jasper W L Hartog; Adriaan A Voors; Stephan J L Bakker; Andries J Smit; Dirk J van Veldhuisen Journal: Eur J Heart Fail Date: 2007-12 Impact factor: 15.534
Authors: C Cuspidi; S Meani; F Negri; V Giudici; C Valerio; C Sala; A Zanchetti; G Mancia Journal: J Hum Hypertens Date: 2009-03-26 Impact factor: 3.012
Authors: David R Sell; Wanjie Sun; Xiaoyu Gao; Christopher Strauch; John M Lachin; Patricia A Cleary; Saul Genuth; Vincent M Monnier Journal: Cardiovasc Diabetol Date: 2016-02-11 Impact factor: 9.951
Authors: C Blanc-Bisson; F L Velayoudom-Cephise; A Cougnard-Gregoire; C Helmer; K Rajaobelina; C Delcourt; L Alexandre; L Blanco; K Mohammedi; M Monlun; V Rigalleau Journal: Cardiovasc Diabetol Date: 2018-06-08 Impact factor: 9.951